Medigen Biotechnology Corp. (TPEX:3176)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
34.15
+1.00 (3.02%)
Apr 29, 2026, 9:30 AM CST
17.76%
Market Cap 4.62B
Revenue (ttm) 1.58B
Net Income (ttm) -108.80M
Shares Out 139.31M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,000
Average Volume 538,345
Open 33.35
Previous Close 33.15
Day's Range 33.15 - 34.30
52-Week Range 28.00 - 35.95
Beta 0.26
RSI 56.33
Earnings Date May 13, 2026

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 3176
Full Company Profile

Financial Performance

In 2025, Medigen Biotechnology's revenue was 1.58 billion, an increase of 15.28% compared to the previous year's 1.37 billion. Losses were -108.80 million, -46.84% less than in 2024.

Financial Statements

News

There is no news available yet.